Response prediction in cancer treatment (p53 adapted cancer therapy)

摘要

The invention discloses a method for diagnosing a tumour patient (i) whether the tumour patient should be treated with a therapy inducing p53 dependent apoptosis or should be treated with a therapy interfering with the cell cycle and/or (ii) whether the tumour patient must not be treated with a therapy inducing p53 dependent apoptosis or must not be treated with a therapy interfering with the cell cycle which is characterised by the following steps: - determining the genetic status of the patient's tumour with respect to p53 by determining in a sample of body fluid or a tissue sample of the patient containing tumour cells or cell-free tumour DNA whether the whole p53 gene is present in native form or whether the p53 gene has one or more mutations; - diagnosing the tumour patient as - (i) a patient who should be treated with a therapy inducing p53 dependent apoptosis if the whole p53 gene is present in native form or as a patient who should be treated with a therapy interfering with the cell cycle if the p53 gene has one or more mutations; and/or - (ii) a patient who must not be treated with a therapy inducing p53 dependent apoptosis if the p53 gene has one or more mutations or as a patient who must not be treated with a therapy interfering with the cell cycle if the whole p53 gene is present in native form.